| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA442: Ixekizumab for treating moderate to severe plaque psoriasis |
|
Medicine details |
|
| Medicine name | ixekizumab (Taltz®) |
| Formulation | 80 mg solution for injection |
| Reference number | 1600 |
| Indication | Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 14/06/2016 |
| NICE guidance | TA442: Ixekizumab for treating moderate to severe plaque psoriasis |